UK earnings, trading statements calendar - next 7 days
23rd May 2025 11:49
| Price | 10.50p on 23-05-2025 at 18:00:07 |
|---|---|
| Change | 0.50p 5% |
| Buy | 11.00p |
| Sell | 10.00p |
| Buy / Sell AGL Shares | |
| Last Trade: | Unknown 114,988.00 at 10.50p |
| Day's Volume: | 3,598,449 |
| Last Close: | 10.50p |
| Open: | 10.00p |
| ISIN: | GB0034330679 |
| Day's Range | 10.50p - 10.50p |
| 52wk Range: | 7.25p - 19.50p |
| Market Capitalisation: | £34m |
| VWAP: | 10.63955p |
| Shares in Issue: | 323m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Angle (AGL) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 114,988 | 10.50p | OTC Trade |
17:07:12 - 23-May-25 |
| Unknown* | 99,100 | 10.50p | Uncrossing Trade |
16:35:18 - 23-May-25 |
| Sell* | 51,843 | 10.3444p | Ordinary |
16:28:04 - 23-May-25 |
| Sell* | 5,000 | 10.35555p | Ordinary |
16:24:12 - 23-May-25 |
| Sell* | 14,224 | 10.369p | Ordinary |
16:19:21 - 23-May-25 |
| Sell* | 55,000 | 10.368p | Ordinary |
16:10:18 - 23-May-25 |
| Buy* | 10,000 | 10.645p | Ordinary |
16:04:20 - 23-May-25 |
| Sell* | 34,912 | 10.366p | Ordinary |
15:14:54 - 23-May-25 |
| Sell* | 3,863 | 10.3566p | Ordinary |
14:16:12 - 23-May-25 |
| Sell* | 14,524 | 10.35555p | Ordinary |
14:10:43 - 23-May-25 |
Angle (AGL) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 23rd May 2025 7:00 am | RNS | Notice of Results |
| 28th Apr 2025 7:00 am | RNS-R | RESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME |
| 21st Mar 2025 7:00 am | RNS | Issue of LTIP Options and Share Options |
| 21st Mar 2025 7:00 am | RNS | Results of Eisai Phase 2 pilot study |
| 6th Feb 2025 7:00 am | RNS-R | Novel findings using Parsortix |
| 29th Jan 2025 7:00 am | RNS | Analysis of CTC-DNA and ctDNA using Illumina assay |
| 24th Jan 2025 10:05 am | RNS-R | Parsortix used in research paper from ETH Zurich |
| 23rd Jan 2025 7:00 am | RNS | Trading Update |
| 26th Sep 2024 7:00 am | RNS | Half-year Report |
| 23rd Sep 2024 7:00 am | RNS | Exclusive agreement for DNA NGS panel |